导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -10.37% | 69/76 |
| 近一周 | -0.06% | 4/84 |
| 近一月 | 0.88% | 7/85 |
| 近一季 | -0.85% | 22/85 |
| 近半年 | -6.29% | 68/78 |
| 近一年 | -13.94% | 67/74 |
| 近两年 | 20.96% | 61/70 |
| 近三年 | 17.00% | 54/62 |
| 成立以来 | 101.67% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-7.69% 57/76 |
-9.67% 73/85 |
- - |
- - |
| 2025 | 18.37% 50/76 |
11.93% 9/74 |
1.21% 65/74 |
9.29% 64/74 |
-4.39% 56/76 |
| 2024 | 16.96% 39/75 |
-1.16% 61/67 |
10.01% 5/72 |
8.85% 19/74 |
-1.18% 47/75 |
| 2023 | -5.71% 33/72 |
3.61% 26/57 |
-4.95% 44/64 |
-1.37% 13/68 |
-2.94% 61/72 |
| 2022 | -4.95% 3/46 |
-8.71% 17/43 |
9.10% 1/45 |
-16.20% 38/45 |
13.88% 5/46 |
| 2021 | -19.69% 38/43 |
2.37% 121/312 |
-3.63% 294/328 |
-13.46% 251/358 |
-5.94% 34/43 |
| 2020 | 18.11% 25/41 |
-8.48% 104/280 |
15.23% 130/295 |
5.53% 89/299 |
6.13% 192/305 |
| 2019 | 25.24% 13/35 |
13.09% 72/258 |
-0.67% 195/268 |
0.51% 132/253 |
10.92% 50/266 |
| 2018 | -8.13% 7/31 |
- - |
- - |
- - |
-7.59% 90/241 |
| 2017 | 29.87% 10/30 |
- - |
- - |
- - |
- - |
| 2016 | 19.69% 2/31 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 诺安油气能源 | 1.4840 | 19.20% |
| 平安港股医疗优选股票(QDII)A | 0.9420 | 17.84% |
| 平安港股医疗优选股票(QDII)C | 0.9385 | 17.67% |
| 创金合信全球医药生物股票发起(QDII)A | 1.5257 | 7.60% |
| 创金合信全球医药生物股票发起(QDII)C | 1.5054 | 7.47% |
| 长城港股价值优选股票(QDII)C | 0.9674 | 1.73% |
| 华宝海外科技股票(QDII-LOF)A | 2.3545 | 0.22% |
| 长城港股价值优选股票(QDII)A | 0.9692 | 0.22% |
| 宏利印度股票(QDII) | 1.3125 | 0.05% |
| 宏利印度股票(QDII)C | 1.3092 | -0.03% |
| 国投瑞银中国价值发现股票 VS. 华宝海外科技股票(QDII(501312) |